PharmAthene to add antibody assets in Theraclone merger

Anthrax vaccine developer PharmAthene is to merge with antibody-focused biotech Theraclone Sciences. PharmAthene said the combined company will have four clinical-stage products, giving it the diversified portfolio desired by management. Article

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.